Last reviewed · How we verify
Midazolam and JNJ-38518168 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Midazolam and JNJ-38518168 (Midazolam and JNJ-38518168) — Janssen Research & Development, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Midazolam and JNJ-38518168 TARGET | Midazolam and JNJ-38518168 | Janssen Research & Development, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Midazolam and JNJ-38518168 CI watch — RSS
- Midazolam and JNJ-38518168 CI watch — Atom
- Midazolam and JNJ-38518168 CI watch — JSON
- Midazolam and JNJ-38518168 alone — RSS
Cite this brief
Drug Landscape (2026). Midazolam and JNJ-38518168 — Competitive Intelligence Brief. https://druglandscape.com/ci/midazolam-and-jnj-38518168. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab